Trop-2 has recently gained attention as a clinical study in patients with triple-negative breast cancer treated with the drug Savituzumab govitecan (SG), a combination of anti-Trop-2 antibody and SN-38 (active metabolite of Irinotecan) could show significant positive effects on progression free and overall survival30. This evidence concerns the gene TACSTD2 and triple-negative breast carcinoma.